Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...
Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...
Hosted on MSN2d
Why NeoGenomics (NEO) Shares Are Trading Lower TodayWhat Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...
NeoGenomics Inc (NEO) reports robust revenue growth and improved margins, while navigating challenges in the pharma segment and ongoing litigation.
Van ECK Associates Corp decreased its stake in shares of Neogen Co. (NASDAQ:NEOG – Free Report) by 20.6% during the 4th ...
NEO Battery Materials plans U.S. expansion for ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 16,230,000 shares, a drop of 5.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback